EP3372587A1 — 3-imidazolines as carbapenemases inhibitors
Assigned to Centre National de la Recherche Scientifique CNRS · Expires 2018-09-12 · 8y expired
What this patent protects
The present application relates to novel 3-imidazolines of formula (I') and (I) below: Wherein Ar 1 , Ar 2 , Ar 3 , and R 1 to R 6 are as defined in the claims. The 3-imidazolines of the invention are useful in antibiotic therapies, in particular as inhibitors of c…
USPTO Abstract
The present application relates to novel 3-imidazolines of formula (I') and (I) below: Wherein Ar 1 , Ar 2 , Ar 3 , and R 1 to R 6 are as defined in the claims. The 3-imidazolines of the invention are useful in antibiotic therapies, in particular as inhibitors of carbapenemases. They are also useful as antibiotics themselves. The present invention also concerns a method for preparing more specifically the 3-imidazolines of formula (I). The present invention further relates to conjugates of said compounds with known antibiotics.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.